476 related articles for article (PubMed ID: 29037205)
1. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Suzuki T; Tada Y; Gladson S; Nishimura R; Shimomura I; Karasawa S; Tatsumi K; West J
Respir Res; 2017 Oct; 18(1):177. PubMed ID: 29037205
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice.
Marques AP; Cunha-Santos J; Leal H; Sousa-Ferreira L; Pereira de Almeida L; Cavadas C; Rosmaninho-Salgado J
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):403-413. PubMed ID: 29154902
[TBL] [Abstract][Full Text] [Related]
3. APELIN-13 AMELIORATES LPS-INDUCED ENDOTHELIAL-TO-MESENCHYMAL TRANSITION AND POST-ACUTE LUNG INJURY PULMONARY FIBROSIS BY SUPPRESSING TRANSFORMING GROWTH FACTOR-Β1 SIGNALING.
Liu H; Shi Q; Tang L; Wang H; Wang D
Shock; 2023 Jan; 59(1):108-117. PubMed ID: 36377383
[TBL] [Abstract][Full Text] [Related]
4. Profiling Proteinic Changes Induced by Vildagliptin Treatment in a Mouse Lung Transplantation Model: The Role of Kininogen-1.
Tang Z; Zhai W; Wang Z; Hu Z; Zhang M
Ann Transplant; 2017 Mar; 22():128-137. PubMed ID: 28265106
[TBL] [Abstract][Full Text] [Related]
5. Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
Lee DS; Lee ES; Alam MM; Jang JH; Lee HS; Oh H; Kim YC; Manzoor Z; Koh YS; Kang DG; Lee DH
Metabolism; 2016 Feb; 65(2):89-101. PubMed ID: 26773932
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway.
Zhang R; Tan Y; Yong C; Jiao Y; Tang X; Wang D
Int Immunopharmacol; 2022 Aug; 109():108805. PubMed ID: 35504205
[TBL] [Abstract][Full Text] [Related]
7. Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in zucker diabetic fatty rat.
Vavrinec P; Henning RH; Landheer SW; Wang Y; Deelman LE; Dokkum RP; Buikema H
Curr Vasc Pharmacol; 2014; 12(6):836-44. PubMed ID: 24066937
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol ameliorates lipopolysaccharide-induced epithelial mesenchymal transition and pulmonary fibrosis through suppression of oxidative stress and transforming growth factor-β1 signaling.
Zhang YQ; Liu YJ; Mao YF; Dong WW; Zhu XY; Jiang L
Clin Nutr; 2015 Aug; 34(4):752-60. PubMed ID: 25234611
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.
Takahashi A; Asakura M; Ito S; Min KD; Shindo K; Yan Y; Liao Y; Yamazaki S; Sanada S; Asano Y; Ishibashi-Ueda H; Takashima S; Minamino T; Asanuma H; Mochizuki N; Kitakaze M
Am J Physiol Heart Circ Physiol; 2013 May; 304(10):H1361-9. PubMed ID: 23504176
[TBL] [Abstract][Full Text] [Related]
10. Endothelial-to-mesenchymal transition in lipopolysaccharide-induced acute lung injury drives a progenitor cell-like phenotype.
Suzuki T; Tada Y; Nishimura R; Kawasaki T; Sekine A; Urushibara T; Kato F; Kinoshita T; Ikari J; West J; Tatsumi K
Am J Physiol Lung Cell Mol Physiol; 2016 Jun; 310(11):L1185-98. PubMed ID: 27106288
[TBL] [Abstract][Full Text] [Related]
11. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats.
Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC
Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961
[TBL] [Abstract][Full Text] [Related]
12. Vildagliptin in clinical practice: a review of literature.
Banerjee M; Younis N; Soran H
Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
14. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
Matsui T; Nishino Y; Takeuchi M; Yamagishi S
Pharmacol Res; 2011 May; 63(5):383-8. PubMed ID: 21320599
[TBL] [Abstract][Full Text] [Related]
15. Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.
Liu Y; Qi Y
Int Immunopharmacol; 2020 Oct; 87():106774. PubMed ID: 32731178
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of vildagliptin against cerebral ischemia in rats.
El-Marasy SA; Abdel-Rahman RF; Abd-Elsalam RM
Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1133-1145. PubMed ID: 30022232
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin ameliorates pulmonary fibrosis in systemic sclerosis mouse model via inhibition of endothelial-to-mesenchymal transition.
Pei B; Zhang N; Pang T; Sun G
Mol Cell Biochem; 2022 Apr; 477(4):995-1007. PubMed ID: 34988855
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
